USFDA issues warning letter to Glenmark Pharmaceuticals’ Goa facility

24 Nov 2022 Evaluate

U.S. Food and Drug Administration (USFDA) has issued warning letter to Glenmark Pharmaceuticals’ Goa (India) facility. The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility. The Company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns at the earliest.

The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1990.65 -9.95 (-0.50%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×